Welcome to Entry Card of Peptide

Details of TopicalPdb ID 1114

PRIMARY INFORMATION

1114

PMID

19709343

Year

2009

Sequence

FLGGLIKIVPAMICA
VTKKC

Name

Ranalexin

Length

N-Terminal Modification

Free

C-Terminal Modification

Free

Linear/ Cyclic

Linear

Chirality

Chemical Modification

None

Origin of Peptide

North American bullfrog, Rana catesbeiana

Nature of Peptide/Cargo

Antimicrobial

Mechanism

Ranalexin and lysostaphin have enhanced bactericidal efficacy in combination compared to the agents used alone in vitro.The cationic loop and hydrophobic tail shared by Ranalexin and polymyxin could represent a fundamental membrane-permeabilizing peptide motif more widely utilized in nature

Cargo Sequence/Structure

AETTNTQQAHTQMSTQSQDVSYGTYYTIDSNGDYHHTPDGNWNQAMFDNKEYSYTFVDAQGHTHYFYNCYPKNANANGSGQTYVNPATAGDNNDYTASQSQQHINQYGYQSNVGPDASYYSHSNNNQAYNSHDGNGKVNYPNGTSNQNGGSASKATASGHAKDASWLTSRKQLQPYGQYHGGGAHYGVDYAMPENSPVYSLTDGTVVQAGWSNYGGGNQVTIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQIAYSGSTGNSTAPHVHFQRMSGGIGNQYAVDPTSYLQSR

Name of cargo

Lysostaphin

Assay

Franz diffusion cell

Enhancer

None

Properties of enhancer

Not applicable

Concentration

10 µl MRSA252 suspension (1·108 CFU ml -1) which was allowed to dry at 25°C; 30 min, 50µl of a treatment solution made up in PBS (100 mg l-1) ranalexin and (1 mg l-1) lysostaphin

Incubation time

30 minutes

Tissue permeability (value with units)

In combination these compounds reduced viable bacteria by 2.83 ± 0.26 log10 CFU

Tissue Sample

Abdominal skin from a 38-year-old white female donor

Ex vivo/In vivo/In vitro

ex vivo

SECONDARY INFORMATION

STRUCTURE

Predicted Structure

SMILES

N[C@@H](Cc1ccccc1)C(=O)N[C@@H]
(CC(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)
N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CCCC[NH3])C(=O)
N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C(C)C)C(=O)
N1CCC[C@H]1C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)
C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]
(CS)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(=O)
N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCC[NH3])
C(=O)N[C@@H](CCCC[NH3])C(=O)N[C@@H](CS)C=O